Stomach cancer

May 1, 2024

NCCN Recommends Universal Testing for Microsatellite Instability by PCR/NGS or Mismatch Repair by IHC for All Newly Diagnosed Gastric Cancer Patients

EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
October 19, 2023

Now Enrolling: EA2212 for Patients with Gastric and/or Gastroesophageal Junction Cancer

This randomized phase 2 study is assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer